InflaRx NV stock (NL0012661870): HC Wainwright raises price target to $8

InflaRx NV, a clinical-stage biopharmaceutical company, saw a positive analyst update as HC Wainwright & Co. maintained its Buy rating and raised the price target to $8 from $6 on May 11, 2026. This adjustment reflects optimism around the company's lead candidate vilobelimab, which has advanced through Phase III trials for hidradenitis suppurativa, according to GuruFocus as of May 12, 2026 and Meyka as of May 12, 2026.

The stock traded at $2.50-$2.605 on Nasdaq as of May 12, 2026, with a market capitalization around $180.7-$188.33 million, according to Meyka as of May 12, 2026. Shares have posted strong one-month gains of approximately 150%, highlighting investor interest in the company's progress in complement system inhibitors.

As of: 12.05.2026

By the editorial team – specialized in equity coverage.

InflaRx NV: core business model

InflaRx NV develops inhibitors targeting the complement activation factor C5a and its receptor C5aR1 for treating inflammatory diseases. The company's lead product, vilobelimab (IFX-1), is an intravenously delivered monoclonal antibody designed to block C5a signaling in acute and chronic inflammatory conditions, according to the company website and Meyka as of May 12, 2026.

Founded in 2007 and headquartered in Jena, Germany, InflaRx focuses on unmet needs in immunology. It went public on Nasdaq in 2017 via an IPO and maintains an ADS structure for US investors, providing exposure to European biotech innovation.

Main revenue and product drivers for InflaRx NV

InflaRx remains pre-revenue with no approved products as of May 2026, relying on cash reserves and potential partnerships for funding. Vilobelimab drives the pipeline, with completed Phase III trials in hidradenitis suppurativa (HS), a chronic skin condition affecting US patients. The company reports a current ratio of 4.16, indicating adequate liquidity despite negative EPS of -$0.74 for the latest period, per Meyka as of May 12, 2026.

Other candidates include INF904, an oral C5aR inhibitor in early clinical stages for inflammatory conditions. Revenue potential hinges on regulatory approvals and commercialization deals, particularly in the US market where biotech demand for novel immunomodulators is high.

Industry trends and competitive position

The complement inhibitor market is expanding, with US sales of related therapies reaching billions annually, driven by autoimmune and inflammatory disease prevalence. InflaRx differentiates via C5a-specific targeting, potentially offering advantages over broader C5 inhibitors like Alexion's Soliris in side effect profiles.

Why InflaRx NV matters for US investors

Listed on Nasdaq as IFRX, InflaRx provides US retail investors direct access to a German biotech with significant US clinical trial exposure. Its pipeline addresses US-prevalent conditions like HS, estimated to affect over 100,000 Americans, aligning with growing demand for targeted therapies amid rising healthcare spending.

Conclusion

InflaRx NV continues to advance its complement inhibitor pipeline, highlighted by the recent HC Wainwright price target increase to $8 and vilobelimab's Phase III progress. While pre-revenue status and clinical risks persist, the company's focus on inflammatory diseases positions it within a high-growth biotech segment relevant to US investors. Market reactions and upcoming data readouts will shape near-term developments.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.